Valerio Therapeutics Stock price

Equities

ALVIO

FR0010095596

Pharmaceuticals

Market Closed - Euronext Paris 12:35:03 2024-03-28 pm EDT 5-day change 1st Jan Change
0.108 EUR -0.92% Intraday chart for Valerio Therapeutics +8.22% -34.55%
Sales 2021 4.06M 4.39M Sales 2022 1.44M 1.56M Capitalization 15.64M 16.88M
Net income 2021 -5M -5.4M Net income 2022 -19M -20.52M EV / Sales 2021 7.53 x
Net cash position 2021 7.95M 8.59M Net cash position 2022 4.45M 4.81M EV / Sales 2022 7.75 x
P/E ratio 2021
-6 x
P/E ratio 2022
-0.76 x
Employees 39
Yield 2021 *
-
Yield 2022
-
Free-Float 73.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.92%
1 week+8.22%
Current month-7.69%
1 month-13.25%
3 months-33.33%
6 months-56.80%
Current year-34.55%
More quotes
1 week
0.10
Extreme 0.098
0.11
1 month
0.09
Extreme 0.09
0.12
Current year
0.09
Extreme 0.09
0.17
1 year
0.09
Extreme 0.09
0.39
3 years
0.09
Extreme 0.09
0.80
5 years
0.09
Extreme 0.09
0.98
10 years
0.09
Extreme 0.09
9.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 21-05-31
Chief Tech/Sci/R&D Officer - -
Director/Board Member - 20-09-16
Members of the board TitleAgeSince
Director/Board Member 64 21-10-13
Director/Board Member 59 -
Director/Board Member 60 11-06-28
More insiders
Date Price Change Volume
24-03-28 0.108 -0.92% 47 875
24-03-27 0.109 +11.00% 126,513
24-03-26 0.0982 -0.20% 62,178
24-03-25 0.0984 -2.09% 62,308
24-03-22 0.1005 +0.70% 22,287

Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT

More quotes
Valerio Therapeutics (formerly Onxeo) is a clinical-stage biotechnology company developing novel cancer drugs by targeting tumor DNA functions through unparalleled mechanisms of action in the highly sought-after field of DNA damage response (DDR). The company focuses on the development of innovative first-in-class or disruptive compounds (in-house, acquired or licensed) from translational research to human clinical proof of concept. Valerio Therapeutics has platON®, its proprietary decoy oligonucleotide chemistry platform. It is dedicated to the generation of innovative new compounds to enrich the company's product portfolio. AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing OX425, a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. OX425 is currently undergoing Investigational New Drug (IND)-enabling preclinical development.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.109 EUR
Average target price
1.2 EUR
Spread / Average Target
+1,000.92%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Valerio Therapeutics - Euronext Paris